Controversies in the Treatment of Peripheral T-cell Lymphoma - Université de Lille
Article Dans Une Revue HemaSphere Année : 2020

Controversies in the Treatment of Peripheral T-cell Lymphoma

Résumé

Peripheral T-cell lymphomas are a heterogeneous group of rare diseases with an aggressive behavior and dismal prognosis. Their classification is complex and still evolving, and several biomolecular markers now help refine the prognosis of specific disease entities, although still have limited impact in tailoring the treatment. First-line treatment strategies can cure only a minority of patients and relapsed-refractory disease still represents the major cause of failure. Frontline autologous transplantation may have an impact in the consolidation of response; however, its role is still questioned as far as complete responses obtained after induction chemotherapy are concerned. Newer drugs are now being evaluated in clinical trials, but effective salvage strategies for those who experience treatment failures are lacking. Here we review and discuss the most controversial aspects of diagnosis and treatment of peripheral T-cell lymphomas.
Fichier principal
Vignette du fichier
Controversies in the Treatment of Peripheral T-cell Lymphoma.pdf (3.63 Mo) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04215545 , version 1 (22-09-2023)

Licence

Identifiants

Citer

Emmanuel Bachy, Alessandro Broccoli, Claire Dearden, Laurence de Leval, Philippe Gaulard, et al.. Controversies in the Treatment of Peripheral T-cell Lymphoma. HemaSphere, 2020, HemaSphere, 4 (5), pp.e461. ⟨10.1097/HS9.0000000000000461⟩. ⟨hal-04215545⟩
8 Consultations
4 Téléchargements

Altmetric

Partager

More